| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2017.07.065 |
| P698 | PubMed publication ID | 28760614 |
| P2093 | author name string | Sixun Yang | |
| Andrea Hulse | |||
| Doran Fink | |||
| R Douglas Pratt | |||
| P2860 | cites work | Two Chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito, Aedes albopictus | Q21090106 |
| A single mutation in chikungunya virus affects vector specificity and epidemic potential | Q21131599 | ||
| Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak | Q21144706 | ||
| A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease | Q21559504 | ||
| Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period | Q21562272 | ||
| Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages | Q24288996 | ||
| A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection | Q24631774 | ||
| Antibody-dependent enhancement of Ebola virus infection | Q24683154 | ||
| Prime-boost immunization strategies against Chikungunya virus | Q24701774 | ||
| Reemergence of chikungunya virus | Q24701780 | ||
| Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand | Q24701788 | ||
| Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection | Q24701792 | ||
| Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus | Q27335008 | ||
| The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic | Q27469278 | ||
| Humanized Monoclonal Antibodies Derived from Chimpanzee Fabs Protect against Japanese Encephalitis Virus In Vitro and In Vivo | Q27486404 | ||
| Seroprevalence and Risk Factors of Chikungunya Virus Infection in Mayotte, Indian Ocean, 2005-2006: A Population-Based Survey | Q27486652 | ||
| SAAG-4 is a novel mosquito salivary protein that programmes host CD4+T cells to express IL-4 | Q27489884 | ||
| Chikungunya virus and the global spread of a mosquito-borne disease | Q28259416 | ||
| Infection with chikungunya virus in Italy: an outbreak in a temperate region | Q29346487 | ||
| An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features | Q29620004 | ||
| US Military contributions to the global response to pandemic chikungunya | Q30224145 | ||
| Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein | Q30516488 | ||
| Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area | Q30851263 | ||
| Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients | Q33375141 | ||
| Mother-to-child transmission of Chikungunya virus infection | Q33376362 | ||
| Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies | Q33517926 | ||
| Host immune response to mosquito-transmitted chikungunya virus differs from that elicited by needle inoculated virus | Q33658669 | ||
| Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. | Q33942533 | ||
| Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates | Q33990566 | ||
| Potentiation of West Nile encephalitis by mosquito feeding | Q33994356 | ||
| Serious acute chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005-2006. | Q34013185 | ||
| Chikungunya virus arthritis in adult wild-type mice | Q34046030 | ||
| Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging | Q34099818 | ||
| Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response | Q34110965 | ||
| Cutting edge: independent roles for IRF-3 and IRF-7 in hematopoietic and nonhematopoietic cells during host response to Chikungunya infection | Q34257289 | ||
| An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952–1953 II. General description and epidemiology | Q34261544 | ||
| A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice | Q34315384 | ||
| Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice | Q34394530 | ||
| Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease | Q34487028 | ||
| Prophylaxis and therapy for Chikungunya virus infection | Q34990306 | ||
| Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection | Q35107882 | ||
| High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines | Q35581782 | ||
| Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection | Q35808631 | ||
| Long-Lasting Immune Protection and Other Epidemiological Findings after Chikungunya Emergence in a Cambodian Rural Community, April 2012 | Q35890653 | ||
| Do we need a vaccine against chikungunya? | Q35933249 | ||
| A role for immune complexes in enhanced respiratory syncytial virus disease | Q36371267 | ||
| Chikungunya virus and prospects for a vaccine | Q36582816 | ||
| An essential role of antibodies in the control of Chikungunya virus infection | Q36914762 | ||
| Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. | Q36961083 | ||
| Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model | Q37065242 | ||
| Chikungunya fever: an epidemiological review of a re-emerging infectious disease | Q37575480 | ||
| Immuno-biology of Chikungunya and implications for disease intervention | Q37593713 | ||
| Chikungunya: a bending reality | Q37595871 | ||
| A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. | Q37643733 | ||
| Epidemiology of Chikungunya infection on Reunion Island, Mayotte, and neighboring countries. | Q37978969 | ||
| Therapeutics and vaccines against chikungunya virus | Q38432812 | ||
| Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus | Q39299364 | ||
| Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial | Q39382188 | ||
| Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection | Q39432395 | ||
| Chikungunya outbreak in the Caribbean region, December 2013 to March 2014, and the significance for Europe | Q40210825 | ||
| Emergence of chikungunya fever on the French side of Saint Martin island, October to December 2013. | Q40210836 | ||
| A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus | Q40245153 | ||
| Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on Réunion | Q40412307 | ||
| A226V mutation in virus during the 2007 chikungunya outbreak in Kerala, India. | Q40414131 | ||
| Tracking epidemic Chikungunya virus into the Indian Ocean from East Africa | Q42062705 | ||
| Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial | Q42199381 | ||
| Spread of chikungunya from the Caribbean to mainland Central and South America: a greater risk of spillover in Europe? | Q42203913 | ||
| Potentiation of vesicular stomatitis New Jersey virus infection in mice by mosquito saliva | Q43000108 | ||
| Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates | Q44140735 | ||
| Development of an attenuated strain of chikungunya virus for use in vaccine production | Q44523303 | ||
| Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island | Q44851009 | ||
| Clinical burden of chikungunya virus infection | Q44851179 | ||
| Chikungunya outbreak in Reunion: epidemiology and surveillance, 2005 to early January 2006. | Q44851468 | ||
| Immunologic interference from sequential administration of live attenuated alphavirus vaccines. | Q44851631 | ||
| Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple | Q45403775 | ||
| Acute rabies death mediated by antibody | Q59058659 | ||
| Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004 | Q80962043 | ||
| P433 | issue | 37 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chikungunya | Q243257 |
| Chikungunya virus | Q15794049 | ||
| P304 | page(s) | 4851-4858 | |
| P577 | publication date | 2017-07-28 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus | |
| P478 | volume | 35 |
Search more.